Cargando…
Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers
Frequently, primary care providers continue to manage the overall medical care of cancer patients. With newer and often more potent antitumor agents, patients may present to their local physicians with drug-induced toxicities such as hypertension induced by vascular endothelial growth factor (VEGF)...
Autores principales: | Escalante, Carmen P., Zalpour, Ali |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099203/ https://www.ncbi.nlm.nih.gov/pubmed/21629798 http://dx.doi.org/10.4061/2011/816897 |
Ejemplares similares
-
Role of Factor Xa Inhibitors in Cancer-Associated Thrombosis: Any New Data?
por: Zalpour, Ali, et al.
Publicado: (2011) -
Vascular Endothelial Growth Factor, from Basic Research to Clinical Applications
por: Ballmer-Hofer, Kurt
Publicado: (2018) -
Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension
por: van Doorn, Leni, et al.
Publicado: (2022) -
Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer.
por: Landriscina, M., et al.
Publicado: (1998) -
Cardiotoxicity with vascular endothelial growth factor inhibitor therapy
por: Touyz, Rhian M., et al.
Publicado: (2018)